Elan, Biogen Stock Up on MS Drug Trial
683001
Patients taking an experimental multiple sclerosis drug developed by Biogen Idec Inc.  and Elan Corp.  experienced far fewer relapses in a clinical trial, data that analysts say could give the drug a dominant market position.
644015
Biotechnology stocks moved higher Wednesday, led by MGI Pharma Inc., which agreed to buy a stake in SuperGen Inc. as part of a licensing deal for SuperGen&#39;s Dacogen drug.
463623
James C. Mullen,Biogen Idec Inc.Chief executive For Biogen Idec Inc., the return of the multiple sclerosis drug Tysabri to the market and continued sales growth for its cash cow, Avonex, were the highlights of 2006. Chief executive James C. Mullen recently spoke with Globe reporter Jeffrey Krasner about the company's progress and the challenges posed by the 2006 election.
142138
Shares of Oragenics Inc. jumped after the biotechnology company reported Tuesday that the Food and Drug Administration allowed it to proceed with safety trials on a lifelong tooth decay protection rinse that
337666
SAN FRANCISCO -- Billionaire investor Carl C. Icahn was given clearance by US antitrust regulators to purchase shares in Biogen Idec Inc., the world's biggest maker of drugs for multiple sclerosis.
139290
Biogen Idec Inc., the third-biggest US biotechnology company, reported a fourth-quarter profit of $48.4 million, helped by sales of its Avonex and Tysabri multiple-sclerosis treatments. Net income was 14 cents a share compared with a net loss of $990.6 million, or $4.03, a year earlier, the Cambridge company said. Revenue almost doubled to $586 million. Biogen is counting on Tysabri, ...
613909
Shares of Biomira Inc. (BRA.TO: Quote, Profile, Research) surged 82 percent on Friday on promising test results for a new lung cancer vaccine developed by Germany&#39;s Merck (MRCG.
407814
Shares in Irish drug group Elan Corp. PLC are expected to be in demand today, as investors react to news that Antegren, its multiple sclerosis (MS) drug now known as Tysabri, was granted accelerated approval by the US FDA last night.
732695
The stock of biotechnology company Biomira (Nasdaq: BIOM), a research and development company specializing in cancer, shot up 146% (to $3.77 a share) from yesterday&#39;s closing price after the company
766094
DUBLIN/NEW YORK  - Patients taking an experimental  multiple sclerosis drug developed by Biogen Idec Inc. BIIB.O  and Elan Corp. ELN.I experienced far fewer relapses in a  clinical trial, data that analysts say could give the drug a  dominant market position.
335265
Biogen Idec Inc.  said on Thursday that fourth-quarter earnings rose on higher sales of its cancer and multiple sclerosis drugs.
621805
First Albany Capital on Wednesday raised SuperGen Inc.&#39;s (SUPG.O: Quote, Profile, Research) stock rating to &quot;buy&quot; from &quot;neutral,&quot; following its cancer-drug deal with MGI Pharma Inc.
747805
DUBLIN, Ireland  - U.S. drug company Biogen Idec  is considering an all-share bid of more than 8.5 billion euros  ($10.6 billion) for Irish peer Elan, a newspaper reported on  Sunday.
747572
TORONTO - Biomira Inc. shares rocketed up more than 118 per cent on Friday on some positive results for a lung cancer vaccine the company is developing with Germany&#39;s Merck.
567020
U.S. drug company Biogen Idec is considering an all-share bid of more than 8.5 billion euros (&#36;10.6 billion) for Irish peer Elan, a newspaper reported on Sunday.
271543
The Food and Drug Administration strongly endorsed Biogen Idec Inc.'s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share. The drug, formerly called Antegren but renamed Tysabri, was developed with Elan Pharmaceuticals of Ireland. The FDA approved Tysabri for use on its own and in ...
26798
Early yesterday evening, Biogen IDEC (Nasdaq: BIIB) and Elan (NYSE: ELN) announced that Tysabri had been approved by the FDA for the treatment of multiple sclerosis (MS).